LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay & Murray LLP (“GPM”) announces that it is investigating potential claims on behalf of investors of Esperion Therapeutics, Inc. ("Esperion" or the "Company") (NASDAQ: ESPR) concerning the Company and its officers’ possible violations of federal securities laws.
On August 17, 2015 Esperion disclosed that during a meeting with the FDA, it was informed that it would not have to complete a cardiovascular outcomes trial (“CVOT”) for approval of ETC-1002. However, on September 28, 2015, Esperion announced that the FDA had actually encouraged the Company to initiate a CVOT and that ETC-1002 would not be approved without completion of a CVOT. On this news shares of Esperion fell dramatically, over $16 per share, or nearly 50%, to close on September 29, 2015 at $18.33 per share.
If you purchased Esperion securities and have suffered a loss on your investment, have information or would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Lesley Portnoy, Esquire, of GPM, 1925 Century Park East, Suite 2100, Los Angeles, California 90067 at 310-201-9150, Toll-Free at 888-773-9224, by email to shareholders@glancylaw.com, or visit our website at http://www.glancylaw.com. If you inquire by email please include your mailing address, telephone number and number of shares purchased.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.
